MinervaX Bolsters Leadership for Pivotal Push in GBS Vaccine Race

COPENHAGEN, Denmark – April 15, 2026 – Danish biotechnology firm MinervaX has significantly strengthened its executive team with two strategic appointments, signaling a major push towards initiating pivotal late-stage trials for its maternal Group B Streptococcus (GBS) vaccine. The company announced that Jamila Louahed, a veteran from GSK's vaccine division, will join as Chief Development Officer, while life science finance expert Hans Henrik Chrois Christensen will take the helm as Chief Financial Officer.

The move comes at a critical inflection point for MinervaX, which aims to be the first to bring an approved GBS vaccine to market. Armed with robust Phase II clinical data and substantial financial backing, these hires are designed to provide the late-stage development and operational expertise necessary to navigate the final, most demanding phases of regulatory approval and commercialization.

A Strategic Power-Up for the Final Stretch

The appointments are a clear statement of intent as MinervaX transitions from a promising clinical-stage company to a potential market leader. Jamila Louahed brings over two decades of experience from pharmaceutical giant GSK, where she played a senior role in vaccine research and development. Her track record of advancing vaccine candidates from discovery through to regulatory approval is seen as invaluable as MinervaX prepares for its registrational trial.

Hans Henrik Chrois Christensen provides the financial acumen required for such a capital-intensive undertaking. With a history of financial leadership at both private and public life science companies, including ImCheck Therapeutics and Exiqon, his experience in managing financing strategies, M&A transactions, and operational scale-up is crucial. Funding a global Phase III trial and building the infrastructure for a potential product launch requires a seasoned financial strategist, a role Christensen is well-equipped to fill.

Per Fischer, Chief Executive Officer of MinervaX, highlighted the significance of the timing. “Jamila and Hans Henrik join us at an important moment for the company as we prepare for the initiation of our pivotal trial,” he stated in the company’s announcement. “Their combined expertise in vaccine development and financial strategy will strengthen our ability to execute and deliver on our long-term ambitions. We are united in our commitment to advancing a first‑in‑class GBS vaccine that has the potential to prevent life-threatening infections affecting families worldwide.”

Confronting a Global Health Crisis

The urgency driving MinervaX and its competitors is rooted in the devastating global impact of Group B Streptococcus. While often harmless in healthy adults, GBS is a leading cause of severe illness in newborns. According to the World Health Organization (WHO), the bacterium is responsible for an estimated 410,000 maternal and infant cases annually, leading to approximately 147,000 tragic stillbirths and infant deaths each year. The disease is also a major contributor to premature births and can cause long-term disabilities like cerebral palsy and hearing loss in survivors.

Currently, the primary preventive measure is administering intravenous antibiotics to mothers during labor, a strategy known as intrapartum antibiotic prophylaxis (IAP). While IAP can reduce the incidence of early-onset GBS disease in the first week of life by about 80%, it has significant limitations. The strategy does not prevent GBS-related stillbirths, preterm labor, or late-onset disease, which occurs from one week to several months after birth. Furthermore, its implementation is challenging in low- and middle-income countries where the disease burden is often highest, due to a lack of systematic screening and healthcare infrastructure.

The clear and pressing unmet need for a prophylactic vaccine has created a high-stakes race among several biopharmaceutical companies. A successful maternal vaccine would work by stimulating the mother to produce protective antibodies, which are then transferred to the fetus through the placenta, providing crucial protection from birth through the first few months of life.

A Novel Vaccine in a Competitive Field

MinervaX's candidate is a protein-only vaccine based on fusions of highly immunogenic domains from the Alpha-like protein (AlpN) family. This innovative approach is designed to provide extremely broad protection, with the company projecting it will be effective against virtually all circulating GBS strains globally—a potential advantage over other vaccine technologies.

The company's confidence is backed by encouraging results from its clinical program. Two Phase II trials (NCT04596878 and NCT05154578) involving 470 pregnant individuals across Denmark, the UK, South Africa, and Uganda have demonstrated that the vaccine is safe, well-tolerated, and highly immunogenic, producing functionally active antibodies. The company has also completed a Phase I trial (NCT05782179) for its vaccine in older adults, another population vulnerable to invasive GBS disease.

However, MinervaX is not alone in this pursuit. Pharmaceutical giant Pfizer is also advancing its GBS vaccine candidate, GBS6, a six-valent polysaccharide conjugate vaccine, which is currently in a large-scale Phase 2/3 study. Similarly, Inventprise, Inc. is developing its own hexavalent conjugate vaccine, which recently entered Phase I/II trials. The competition underscores the estimated $1 billion annual market potential for a successful maternal GBS vaccine.

Incoming Chief Development Officer Jamila Louahed commented on the strength of the company's approach. “MinervaX is advancing one of the most promising approaches to GBS,” she remarked. “The science is robust, the data are strong, and the program is ready for its next stage of development.”

Financial Fortitude for the Path Ahead

Advancing a vaccine through pivotal trials and to the market is a monumental and costly endeavor. MinervaX has proactively built a formidable financial foundation to support this journey. Since its founding in 2010, the company has raised approximately EUR 200 million.

Recent financing rounds have been particularly successful. In late 2023, MinervaX completed an upsized EUR 54 million financing, attracting top-tier investors EQT Life Sciences and OrbiMed, alongside a strong syndicate of existing backers including Novo Holdings, Sanofi Ventures, and Wellington Partners. This followed a EUR 72 million financing package in 2022. As a result, the company now holds financial reserves exceeding €125 million, specifically earmarked to launch its Phase III trial.

This strong investor confidence is critical as the company enters its most cash-intensive phase. Hans Henrik Chrois Christensen, the new CFO, acknowledged this pivotal moment. “MinervaX is at a pivotal point, having made solid progress towards starting its Pivotal trial in the maternal indication, supported by strong advisors and internationally renowned investors,” he stated. “Building the financial and operational strength required at this stage is critical to delivering the first approved GBS vaccine to patients worldwide.”

With a strengthened leadership team, a promising and differentiated vaccine candidate, and a robust balance sheet, MinervaX appears well-positioned for the final and most challenging leg of its journey. The initiation of its pivotal trial will be a closely watched milestone in the global effort to conquer a silent but deadly threat to mothers and their newborns.